Novavax Inc is a biotechnology company focused on the development and commercialization of innovative vaccines to prevent infectious diseases. The company harnesses its proprietary nanoparticle technology and adjuvant platforms to create safe and effective immunizations. Novavax aims to address public health challenges by producing vaccines for various diseases, prominently including those caused by emerging viral pathogens. Through its research and clinical trials, Novavax is committed to enhancing global health outcomes and responding efficiently to viral outbreaks. Read More
Sen. Elizabeth Warren (D-Mass.) is sounding the alarm on President Donald Trump's attempts at overhauling leadership at the Centers for Disease Control and Prevention, warning of risks to public health.
FDA approves Pfizer, Moderna, and Novavax Covid vaccines for high-risk groups as emergency authorizations end and vaccines transition to full marketing.
The Trump administration may remove COVID-19 vaccines from the U.S. market as RFK Jr.'s allies gain influence at HHS, with a new vaccine task force led by a known skeptic.
Bank of America’s downgrade to ‘Underperform’ with a $7 target deepened concerns over Sanofi’s limited commercialization of Nuvaxovid and higher hurdles for future partnerships.
Novavax beats Q2 expectations with $239 million in revenue, lifts 2025 guidance, and reports profit as costs decline and commercial rights shift to Sanofi.
This week, from August 4th to August 10th, 2025, marks a busy period in the second-quarter earnings season, with hundreds of companies across various sectors scheduled to report their financial results. These earnings calls are crucial events for investors, analysts, and the broader market, as they provide insights into corporate
Novavax (NVAX) stock surges 5.5% pre-market after Q2 2025 earnings crush estimates with $239M revenue and $0.62 EPS, fueled by Sanofi deal and FDA approval for Nuvaxovid.
Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results.
